There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Evotec AG (EVO – Research Report), Lyra Therapeutics (LYRA – Research Report) and Alpine Immune Sciences (ALPN – Research Report) with bullish sentiments.
Evotec AG (EVO)
H.C. Wainwright analyst Douglas Tsao maintained a Buy rating on Evotec AG today and set a price target of $14.00. The company’s shares closed last Wednesday at $12.02.
According to TipRanks.com, Tsao is a 4-star analyst with an average return of
Currently, the analyst consensus on Evotec AG is a Strong Buy with an average price target of $14.00.
See today’s best-performing stocks on TipRanks >>
Lyra Therapeutics (LYRA)
Lyra Therapeutics received a Buy rating and a $12.00 price target from H.C. Wainwright analyst Matthew Caufield today. The company’s shares closed last Wednesday at $3.36.
According to TipRanks.com, Caufield is a 5-star analyst with an average return of
Currently, the analyst consensus on Lyra Therapeutics is a Moderate Buy with an average price target of $12.50.
Alpine Immune Sciences (ALPN)
H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Alpine Immune Sciences today and set a price target of $17.00. The company’s shares closed last Wednesday at $12.67.
According to TipRanks.com, Pantginis is ranked 0 out of 5 stars with an average return of
Currently, the analyst consensus on Alpine Immune Sciences is a Strong Buy with an average price target of $16.75.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on EVO:
